Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

导出 LinkOut

翻译打印收藏纠错

第一作者： Luise,Rogg

第一单位： ViiV Healthcare, Durham, NC, USA.

作者： Luise,Rogg ^[1] ; Mark,Underwood ^[1] ; Nathan,Hanan ^[2] ; Jose R,Castillo-Mancilla ^[1] ; Lesley,Kahl ^[3] ; Fiona,Halliday ^[4] ; Gabriela L,Ghita ^[2] ; Jerry L,Jeffrey ^[1] ; Stuart,Byrne ^[5] ; Tsukasa,Onodera ^[5] ; Joseph,Horton ^[6] ; Martin,Gartland ^[1]

作者单位： ViiV Healthcare, Durham, NC, USA. ^[1] GSK, Collegeville, PA, USA. ^[2] ViiV Healthcare, London, UK. ^[3] GSK, London, UK. ^[4] Shionogi & Co., LTD., Osaka, Japan. ^[5] Parexel International, Durham, NC, USA. ^[6]

关键词 integrase strand transfer inhibitor pharmacokinetics resistance safety third-generation

DOI 10.1093/cid/ciaf135

PMID 40117383

发布时间 2025-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical infectious diseases

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Clinical infectious diseases

相似文献

Clinical infectious diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Clinical infectious diseases

相似文献

Clinical infectious diseases

相关期刊

检索历史清除